Stay updated with breaking news from Peer Exchange. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts discuss the evolving landscape of multiple myeloma treatment, exploring real-world evidence's role in shaping the future and its impact on clinical decisions, rare subgroups, and treatment sequencing.
Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.
Safety considerations for BTKi use in CLL and SLL treatment are highlighted.
Dr Haumschild drives a discussion surrounding the role of bruton kinase inhibitors for treating CLL and SLL.
Pharmacists discuss tailoring myelofibrosis treatments to individual patient needs, focusing on symptom management, preferences, and challenges in care team collaboration.